Overview
BWAY market data
Price History
BWAY price chart
Valuation & Profitability
- P/E (TTM)
- 74.45 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.19 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.75 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $272.00 – $993.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $2K · P/B 5.31 · P/S 13.29.
Company news
BrainsWay Announces $3M Minority Equity Investment In Radial HealthBenzinga · Jul 20, 2026, 11:32 AM
BTIG Initiates Coverage On BrainsWay with Buy Rating, Announces Price Target of $18Benzinga · Jul 20, 2026, 10:15 AM
BrainsWay To Invest $500,000 For Minority Position In Sound Minds In The Form Of Preferred, Annually Compounding SecurityBenzinga · Jul 16, 2026, 11:34 AM
HC Wainwright & Co. Reiterates Buy on BrainsWay, Maintains $17 Price TargetBenzinga · Jul 2, 2026, 11:00 AM
BrainsWay Presents New Data On Enhancements In Participants With Comorbid Post-Traumatic Stress Disorder, Major Depressive Disorder With Deep Transcranial Magnetic StimulationBenzinga · Jun 29, 2026, 11:40 AM
BrainsWay Expands Insurance Coverage for Faster Depression TreatmentBenzinga · Jun 22, 2026, 11:40 AM
BrainsWay Presents New Prospective 12-Month Durability Data Demonstrating Sustained Clinical Benefits Following Accelerated Deep Transcranial Magnetic Stimulation For Major Depressive DisorderBenzinga · Jun 9, 2026, 11:45 AM
HC Wainwright & Co. Maintains Buy on BrainsWay, Raises Price Target to $17Benzinga · May 26, 2026, 10:41 AM
BrainsWay To Invest $1.5M Initially, With Potential For Additional $1.5M Via Milestone-Based Investments, For Minority Position In Hopemark In Form Of Preferred, Annually Compounding SecurityBenzinga · May 18, 2026, 11:40 AM
Full Transcript: BrainsWay Q1 2026 Earnings CallBenzinga · May 13, 2026, 1:46 PM